000			04074nam a2200505 i 4500
001			EBC4745624
003			MiAaPQ
005			20240121103356.0
006			m o d |
007			cr cnu||||||||
008			160715t20172017njua ob 001 0 eng|d
020			_z9781119060680 (cloth)
020			_z9781119060680
020			_a9781119060802 _q(electronic bk.)
035			_a(MiAaPQ)EBC4745624
035			_a(Au-PeEL)EBL4745624
035			_a(CaPaEBR)ebr11300198
035			_a(CaONFJC)MIL978150
035			_a(OCoLC)964410742
040			_aMiAaPQ _beng _erda _epn _cMiAaPQ _dMiAaPQ
050		4	_aRS431.A64 _bA58 2017
082	0		_a615.7/98 _223
130	0		_aAntibody-drug conjugates (Olivier)
245	1	0	_aAntibody-drug conjugates : _bfundamentals, drug development, and clinical outcomes to target cancer / _cedited by Kenneth J. Olivier Jr. and Sara A. Hurvitz.
264		1	_aHoboken, New Jersey : _bJohn Wiley & Sons, Incorporated, _c[2017]
264		4	_c2017
300			_a1 online resource (566 pages) : _bcolor illustrations
336			_atext _2rdacontent
337			_acomputer _2rdamedia
338			_aonline resource _2rdacarrier
504			_aIncludes bibliographical references and index.
505	0		_aTypical antibody-drug conjugates / John Lambert -- Selecting optimal ADC targets using indication-dependent or indication-independent approaches / Robert Hollingsworth and Jay Harper -- Antibody drug conjugates : an overview of the CMC and characterization process / Janet Wolfe and Phillip Ross -- Linker and conjugation technology and improvements / Riley Ennis and Sourav Sinha -- Formulation and stability / Kouhei Tsumoto, Anthony Young, and Satoshi Ohtake -- QC assay development / Xiao-Hong Chen and Mate Tolnay -- Occupational health and safety aspects of ADCs and their toxic payloads / Robert Sussman and John Farris -- Bioanalytical strategies enabling successful ADC translation / Xiaogang Han, Lindsay King, and Steve Hansel -- Nonclinical pharmacology and mechanistic modeling of antibody drug conjugates in support of human clinical trials / Brian J. Schmidt, Chin Pan, Heather E. Vezina, Huadong Sun, Douglas D. Leipold, and Manish Gupta -- Pharmacokinetics of antibody-drug conjugates / Amrita Kamath -- Path to market approval : regulatory perspective of ADC nonclinical safety assessments / Stacey Ricci and Natalie Simpson -- Antibody drug conjugates : clinical strategies and applications / Heather E. Vezina, Lucy Lee, Brian J. Schmidt, Manish Gupta -- Antibody-drug conjugates (ADCs) in clinical development / Patricia LoRusso and Joseph McLaughlin -- ADCs approved for use : Trastuzumab emtansine (Kadcyla, T-DM1) in patients with previously treated HER2-positive metastatic breast cancer / Gail Lewis Phillips, Sanne de Hass, Sandhya Girish, and Ellie Guardino -- ADCs approved for use : Brentuximab Vedotin / Sven DeVos and Monica Mead -- Radioimmunotherapy / Jeffrey Wong and Savita Dandapani -- Radiolabeled antibody-based imaging in clinical oncology / Bart Hendriks and Daniel Gaddy -- Antibody-drug conjugates : the next evolution in the cure for cancer -- William C. Olson and Amy Q. Han.
588			_aDescription based on print version record.
590			_aElectronic reproduction. Ann Arbor, MI : ProQuest, 2016. Available via World Wide Web. Access may be limited to ProQuest affiliated libraries.
650		0	_aAntibody-toxin conjugates.
650		0	_aMonoclonal antibodies.
650		0	_aAntineoplastic agents.
650		0	_aTumors _xTreatment.
655		4	_aElectronic books.
700	1		_aOlivier, Kenneth J., _cJr., _d1968- _eeditor.
700	1		_aHurvitz, Sara A., _d1970- _eeditor.
776	0	8	_iPrint version: _aAntibody-drug conjugates (Olivier) _tAntibody-drug conjugates : fundamentals, drug development, and clinical outcomes to target cancer. _dHoboken, New Jersey : John Wiley & Sons, Incorporated, [2017] _z9781119060680 _w(DNLM)101688103
797	2		_aProQuest (Firm)
856	4	0	_uhttps://ebookcentral.proquest.com/lib/bacm-ebooks/detail.action?docID=4745624 _zClick to View
999			_c276005 _d276005